Back to search results

Splanchnic Nerve Block for Heart Failure

This study is looking into a new approach for heart failure with reduced ejection fraction (HFrEF), a condition where your heart can't pump enough blood. Researchers are testing a procedure called a Splanchnic nerve block. This involves a catheter-based ablation (a procedure using heat to remove tissue) on a specific nerve to see if it helps with heart failure symptoms. You might be able to join if you are over 18, have an HFrEF diagnosis with a left ventricular ejection fraction (a measure of how well your heart pumps blood) less than 50%, and have stable heart failure medication for at least a month. The study will measure how many participants experience cardiovascular death, heart attack, or major complications requiring long hospital stays or surgery within one month after the procedure. The study plans to enroll 54 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It involves 54 participants and compares the Splanchnic nerve block to a sham-control procedure.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least one month after the intervention to check for cardiovascular death, heart attack, or major complications.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06733012

Splanchnic X: Splanchnic Nerve Block in Heart Failure With Reduced Ejection Fraction

Recruiting
NAAges 18+InterventionalTreatment
Duke University
~54 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:Splanchnic nerve blockSham-control procedure

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with cardiovascular death
Measured over 1 month post intervention
+4 more outcomes measured

Conditions

Heart Failure

Explore related trials

Heart Failure

NCT06733012

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Duke

    Durham, North Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Manesh Patel, MD · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Marat Fudim
[email protected]
919-681-5816
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \> 18 years
Established diagnosis of HFrEF with left ventricular ejection fraction \<50%
NYHA II-III symptoms
Stable HF drug regimen for the preceding 1 month
Wedge pressure \>/=15 mmHg at rest or \>/=20 mmHg with peak stress on the initial invasive exercise testing
Glomerular filtration rate ≥ 15 mL/min per 1.73 m2
Heart rate with activity such as the 6 min walk increases by at least 10 beats

Exclusion

Type I myocardial infarction within 3 months
Infiltrative (i.e., amyloid) or hypertrophic cardiomyopathy
Uncontrolled atrial (heart rate \>100bpm) or ventricular arrhythmia
Chronic oxygen use \>2L
Hypersensitivity to albumin and pregnancy
History or scoliosis
Orthostatic hypotension (including a drop of pulse pressure with standing of more than 10)

What this trial measures

  • Number of participants with cardiovascular death1 month post intervention
  • Number of participants with acute myocardial infarction1 month post intervention
  • Number of participants with major vascular complications resulting prolonged hospitalization or surgical intervention1 month post intervention
  • Number of participants with stroke1 month post intervention
  • Change in exercise pulmonary capillary wedge pressure (PCWP) post splanchnic nerve block (SNB)Baseline to 3 months post splanchnic nerve block (SNB)

    Pulmonary capillary wedge pressure (PCWP) is measured by inserting a catheter with a balloon tip into a central vein and advancing it into a branch of the pulmonary artery. The catheter measures changing pressures in the pulmonary vessels. The upper limit of normal for PCWP is 12 mm Hg.